SEC Form 4 · accession 0001209191-19-018545
Odonate Therapeutics, Inc. · ODT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Kevin C Tang
Officer — Chief Executive Officer · Director · 10% Owner
TANG CAPITAL PARTNERS LP
10% Owner
TANG CAPITAL MANAGEMENT LLC
10% Owner
John G Lemkey
Officer — Chief Operating Officer
Michael S Hearne
Officer — Chief Financial Officer
Period of report
Mar 7, 2019
Accepted (ET)
Mar 11, 2019 · 5:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001717452
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 7, 2019 | P | 19,036 | $16.5627 | A | 12,965,074 | I | By LP |
| Common StockF3,F2 | Mar 7, 2019 | P | 964 | $17.1526 | A | 12,966,038 | I | By LP |
| Common StockF4,F2 | Mar 7, 2019 | P | 20,000 | $17.4955 | A | 12,986,038 | I | By LP |
| Common StockF5,F2 | Mar 8, 2019 | P | 22,863 | $18.1039 | A | 13,008,901 | I | By LP |
| Common StockF6,F2 | Mar 8, 2019 | P | 77,137 | $18.9361 | A | 13,086,038 | I | By LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $16.13 to $17.12. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 6 herein.
- F2The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
- F3The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $17.13 to $17.22.
- F4The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $17.22 to $17.59.
- F5The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $17.55 to $18.51.
- F6The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $18.55 to $19.54.